CR20140291A - Metodos y composiciones para tratar enfermedades virales - Google Patents

Metodos y composiciones para tratar enfermedades virales

Info

Publication number
CR20140291A
CR20140291A CR20140291A CR20140291A CR20140291A CR 20140291 A CR20140291 A CR 20140291A CR 20140291 A CR20140291 A CR 20140291A CR 20140291 A CR20140291 A CR 20140291A CR 20140291 A CR20140291 A CR 20140291A
Authority
CR
Costa Rica
Prior art keywords
compositions
methods
viral diseases
treat viral
infections
Prior art date
Application number
CR20140291A
Other languages
English (en)
Inventor
Shirit Einav
Rina Barouch-Bentov
Gregory Neveu
Amotz Zivav
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of CR20140291A publication Critical patent/CR20140291A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12C—BEER; PREPARATION OF BEER BY FERMENTATION; PREPARATION OF MALT FOR MAKING BEER; PREPARATION OF HOPS FOR MAKING BEER
    • C12C1/00—Preparation of malt
    • C12C1/18—Preparation of malt extract or of special kinds of malt, e.g. caramel, black malt
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La invención proporciona un método para tratar infecciones virales y co-infecciones mediante el uso de agentes inhibidores que evitan que los motivos de proteína estructural viral únicos se unan con las proteínas huésped de la familia de proteínas adaptadoras de clatrina y evitar posteriormente la replicación viral.
CR20140291A 2011-12-06 2014-06-18 Metodos y composiciones para tratar enfermedades virales CR20140291A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161567491P 2011-12-06 2011-12-06
PCT/US2012/068167 WO2013086133A1 (en) 2011-12-06 2012-12-06 Methods and compositions for treating viral diseases

Publications (1)

Publication Number Publication Date
CR20140291A true CR20140291A (es) 2014-10-28

Family

ID=48574863

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140291A CR20140291A (es) 2011-12-06 2014-06-18 Metodos y composiciones para tratar enfermedades virales

Country Status (13)

Country Link
US (2) US9364484B2 (es)
EP (1) EP2787999B1 (es)
CN (1) CN104066432B (es)
AU (1) AU2012347785B2 (es)
BR (1) BR112014013649A2 (es)
CO (1) CO7230337A2 (es)
CR (1) CR20140291A (es)
MX (1) MX349036B (es)
MY (1) MY171759A (es)
PE (1) PE20142102A1 (es)
PH (1) PH12014501268B1 (es)
SG (1) SG11201402899TA (es)
WO (1) WO2013086133A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016054468A1 (en) * 2014-10-03 2016-04-07 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating enveloped viruses
EP4138829A1 (en) * 2020-04-21 2023-03-01 Lexicon Pharmaceuticals, Inc. Aak1 inhibitors for use in treating viral infections

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6241704B1 (en) 1901-11-22 2001-06-05 Sims Deltec, Inc. Drug pump systems and methods
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US3760984A (en) 1971-09-29 1973-09-25 Alza Corp Osmotically powered agent dispensing device with filling means
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3923426A (en) 1974-08-15 1975-12-02 Alza Corp Electroosmotic pump and fluid dispenser including same
US4036228A (en) 1975-09-11 1977-07-19 Alza Corporation Osmotic dispenser with gas generating means
US3987790A (en) 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4016880A (en) 1976-03-04 1977-04-12 Alza Corporation Osmotically driven active agent dispenser
US4111202A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4111203A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system with means for improving delivery kinetics of system
US4203442A (en) 1977-08-29 1980-05-20 Alza Corporation Device for delivering drug to a fluid environment
US4203440A (en) 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
US4210139A (en) 1979-01-17 1980-07-01 Alza Corporation Osmotic device with compartment for governing concentration of agent dispensed from device
US4360019A (en) 1979-02-28 1982-11-23 Andros Incorporated Implantable infusion device
US4350155A (en) 1980-04-02 1982-09-21 Medtronic, Inc. Body implantable medical infusion system
US4692147A (en) 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4627850A (en) 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
US4725852A (en) 1985-05-09 1988-02-16 Burlington Industries, Inc. Random artificially perturbed liquid apparatus and method
US4865845A (en) 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
US5057318A (en) 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5059423A (en) 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5112614A (en) 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5234692A (en) 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234693A (en) 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5137727A (en) 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5545143A (en) 1993-01-21 1996-08-13 T. S. I. Medical Device for subcutaneous medication delivery
CA2160457A1 (en) 1993-04-19 1994-10-27 Stuart A. Kauffman Random chemistry for the generation of new compounds
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5443450A (en) 1994-04-29 1995-08-22 Medtronic, Inc. Medication delivery device and method of construction
DE19509634C1 (de) 1995-03-17 1996-03-28 Fresenius Ag Implantierbare Infusionspumpe
US5643207A (en) 1995-04-28 1997-07-01 Medtronic, Inc. Implantable techniques for infusing a therapeutic agent with endogenous bodily fluid
PT1238659E (pt) 1996-02-02 2005-01-31 Alza Corp Libertacao sustentada de um agente activo utilizando um sistema implantavel
US5976109A (en) 1996-04-30 1999-11-02 Medtronic, Inc. Apparatus for drug infusion implanted within a living body
US5820589A (en) 1996-04-30 1998-10-13 Medtronic, Inc. Implantable non-invasive rate-adjustable pump
US5990276A (en) 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
ATE271063T1 (de) 1996-10-16 2004-07-15 Icn Pharmaceuticals Purin-l-nukleoside, deren analoga und verwendungen
IL129407A0 (en) 1996-10-18 2000-02-17 Vertex Pharma Inhibitors of serine proteases particularly hepatitis C virus NS3 protease pharmaceutical compositions containing the same and the use thereof
US6171276B1 (en) 1997-08-06 2001-01-09 Pharmacia & Upjohn Ab Automated delivery device and method for its operation
ES2241157T3 (es) 1997-08-11 2005-10-16 Boehringer Ingelheim (Canada) Ltd. Peptidos inhibidores de la hepatitis c.
NZ503263A (en) 1997-08-11 2002-10-25 Boehringer Ingelheim Ca Ltd Hepatitis C NS3 protease inhibitor peptides and peptide analogues
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US6423695B1 (en) 1998-01-13 2002-07-23 Ribapharm, Inc. Cytokine related treatments of disease
AU3376699A (en) 1998-03-31 1999-10-18 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
AU756627B2 (en) 1998-07-27 2003-01-16 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Diketoacid-derivatives as inhibitors of polymerases
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6440985B1 (en) 1998-09-04 2002-08-27 Viropharma Incorporated Methods for treating viral infections
US6277830B1 (en) 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
US6308099B1 (en) 1998-11-13 2001-10-23 Intermedics Inc. Implantable device and programmer system which permits multiple programmers
US6198966B1 (en) 1999-02-26 2001-03-06 Medtronic, Inc. Recirculating implantable drug delivery system
US6464687B1 (en) 1999-03-09 2002-10-15 Ball Semiconductor, Inc. Implantable drug delivery system
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
DE19915914C2 (de) 1999-04-08 2001-04-26 Willi Foldenauer Fütterungsvorrichtung mit Funktionsrandgestaltung
AU763356C (en) 1999-12-27 2004-08-26 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
US6624290B2 (en) 2000-02-08 2003-09-23 Schering Corporation Azapeptides useful in the treatment of Hepatitis C
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
DE10031274A1 (de) 2000-06-27 2002-01-10 Bosch Gmbh Robert Wischarm für Kraftfahrzeuge
AU2001273096B8 (en) 2000-06-28 2005-10-13 Dana-Farber Cancer Institute, Inc. PD-L2 molecules: novel PD-1 ligands and uses therefor
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
WO2002060926A2 (en) 2000-11-20 2002-08-08 Bristol-Myers Squibb Company Hepatitis c tripeptide inhibitors
MXPA03006514A (es) 2001-01-22 2004-12-02 Merck & Co Inc Derivados de nucleosidos como inhibidores de polimerasa de acido ribonucleico viral dependiente de acido ribonucleico.
WO2002069903A2 (en) 2001-03-06 2002-09-12 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
WO2002089731A2 (en) 2001-05-03 2002-11-14 Stanford University Agents for treatment of hcv and methods of use
EP1256628A3 (en) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
ATE438637T1 (de) 2001-06-11 2009-08-15 Virochem Pharma Inc Thiophenderivate als antivirale mittel gegen flavivirus-infektion
CA2449999C (en) 2001-06-11 2012-07-31 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
US6841566B2 (en) 2001-07-20 2005-01-11 Boehringer Ingelheim, Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US7582428B2 (en) 2003-08-22 2009-09-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for identifying anti-HCV agents
US20070060537A1 (en) * 2005-04-28 2007-03-15 Proteologics, Inc. Methods and compositions for inhibiting viral infections
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
MX349137B (es) 2005-06-08 2017-07-13 Dana-Farber Cancer Inst Metodos y composiciones para el tratamiento de infecciones persistentes y cancer por inhibicion de la ruta de muerte celular programada (pd-1).
US7550400B2 (en) 2005-08-02 2009-06-23 Exxonmobil Chemical Patents Inc. Multiple layer nonwoven fabric structures
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7655419B2 (en) 2006-08-25 2010-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for identifying anti-HCV agents
US20110097332A1 (en) * 2007-08-06 2011-04-28 Martina Buck Composition and Method of Use for HCV Immunization
US8895598B2 (en) 2007-09-18 2014-11-25 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating a flaviviridae family viral infection, compositions for treating a flaviviridae family viral infection, and screening assays for identifying compositions for treating a flaviviridae family viral infection
JP2012503619A (ja) * 2008-09-26 2012-02-09 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｈｃｖ感染に対する抗ウイルス治療のための標的としての宿主細胞キナーゼ

Also Published As

Publication number Publication date
US20150057267A1 (en) 2015-02-26
PH12014501268A1 (en) 2014-09-08
PH12014501268B1 (en) 2014-09-08
CO7230337A2 (es) 2015-03-31
SG11201402899TA (en) 2014-07-30
EP2787999A1 (en) 2014-10-15
MX349036B (es) 2017-07-07
MY171759A (en) 2019-10-28
US10869873B2 (en) 2020-12-22
CN104066432B (zh) 2017-06-13
EP2787999B1 (en) 2019-01-23
BR112014013649A2 (pt) 2020-10-27
US9364484B2 (en) 2016-06-14
PE20142102A1 (es) 2015-01-04
CN104066432A (zh) 2014-09-24
MX2014006850A (es) 2014-11-25
AU2012347785B2 (en) 2017-03-16
AU2012347785A1 (en) 2014-06-26
WO2013086133A1 (en) 2013-06-13
EP2787999A4 (en) 2015-05-13
US20170000802A1 (en) 2017-01-05

Similar Documents

Publication Publication Date Title
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CO2017012267A2 (es) Compuestos de naftiridina como inhibidores de la quinasa jak
DOP2018000026A (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
GT201600147A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
BR112018000691A2 (pt) inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
SMT201600398B (it) Inibitori di proteina chinasi (varianti), uso di questi nel trattamento di malattie oncologiche e composizione farmaceutica basata su questi
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
BR112017009648A2 (pt) composto, métodos para tratamento de doenças alérgicas ou outras condições inflamatórias ou prevenção de doença, de rinite alérgica ou asma, composição, e, uso de um composto.
EA201791576A1 (ru) Ингибитор jak
EA201791688A1 (ru) Применение prg4 в качестве противовоспалительного средства
CL2014001547A1 (es) Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales.
CR20110608A (es) Derivados de 1h-imidazo-[4,5-c]-quinolinona
BR112014009006B8 (pt) Compostos heterocíclicos e métodos de uso dos mesmos
BR112016016916A8 (pt) uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae)
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
ECSP14000606A (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
CR20150390A (es) Inhibidores de la yodoproteina basada en 2,3-dihidroimidazol[1,2-c]pirimidin-5(1-h)-ona-asociada a la fosfolipasa a2 (lp-pla2)
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
BR112017002852A2 (pt) compostos de azetidiniloxifenilpirrolidina